U.S., Sept. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07161037) titled 'Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants' on Aug. 29.
Brief Summary: The purpose of the study is to evaluate the effect of VX-407 on height-adjusted total kidney volume (htTKV), safety, tolerability, and pharmacokinetics (PK) of VX-407.
Study Start Date: Sept. 26
Study Type: INTERVENTIONAL
Condition:
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Intervention:
DRUG: VX-407
Tablets for oral administration.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Vertex Pharmaceuticals Incorporated
Published by HT Digital Content Services with permission from Health Daily Diges...